[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gbs\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gbs":36},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":26,"startDateStruct":29,"completionDateStruct":31,"leadSponsor":33,"locationsCount":5},"100429358",false,"NCT04871035","Immunoadsorption Versus Plasma Exchange for Treatment of Guillain-Barré Syndrome (GBS)","IPET-GBS","Inclusion Criteria:\n\n* Diagnosis of Guillain-Barré Syndrome according to the diagnostic criteria proposed by Doorn et al. (Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome, Lancet neurology 2008)\n* age 18 years or above\n\nExclusion Criteria:\n\n* Clinical or laboratory (C-reactive protein 20 mg\u002Fl or above, or evidence of nitrite-positive urinary tract infection) evidence of manifest systemic infection\n* Intake of angiotensin converting enzyme inhibitor within1 weeks before first treatment\n* Other contraindications against immunoadsorption or plasma exchange","ALL","18 Years",{"count":18,"type":19},20,"ESTIMATED","OBSERVATIONAL","This is an observations study evaluating safety and efficacy of immunoadsorption compared to plasma exchange in Guillain-Barré Syndrome.",[23],"GBS","RECRUITING","2026-04-30",{"date":27,"type":28},"2026-05-01","ACTUAL",{"date":30,"type":28},"2021-04-28",{"date":32,"type":19},"2027-09-01",{"name":34,"class":35},"University of Ulm","OTHER",""]